Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.
"We are pleased to provide pharmacists and consumers with the authorized generic of Olux® - a trusted brand product," said Prasco Chief Executive Officer E. Thomas Arington. "As a Prasco authorized generic, Clobetasol Propionate Foam will provide patients with the same quality and experience as the brand product," stated Arington. "We are especially pleased to expand our relationship with Stiefel and GSK, leaders in the pharmaceutical industry."
"Through our arrangement with Prasco, GlaxoSmithKline is able to expand patient access to our products by bringing brand quality to the generic marketplace," said Bill Humphries, President, Stiefel, a GSK company. "We are proud of our arrangement with Prasco, a known leader in authorized generics."